Aims/Objectives: Cisplatin (CIS) is widely used in the treatment of various malignant tumors. The aim of study is to determine the potential protective effects of protocatechuic acid (PCA) on the brain in neurotoxicity induced by CIS in rats.Materials and methods: Forty rats were divided into four groups: 1-Control group: 2- PCA group: PCA was administered orally at a dose of 100 mg/kg/day for 5 weeks. 3-CIS group: 5 mg/kg/week of CIS was administered intraperiteonally 4-PCA + CIS group: The rats were given PCA orally daily for 5 weeks and CIS of 5 mg/kg/week. The brain tissues were used for histopathological examinations and for total antioxidant capacity (TAC), total oxidative state (TOS), oxidative stress index (OSI), tumornecrosis factor-alpha (T NF-α), interleukin 6 (IL-6) Interleukin 1 beta (IL-1β), acetylcholinesterase (AChE), glutamate, gamma aminobutyric acid (GABA), dopamine analyzes in ELISA. WBC, RBC, hemoglobin and hematocrit levels were measured.Results: PCA + CIS group compared to CIS group TOS, OSI, T NF-α, IL-6, IL-1β, AChE, glutamate, WBC levels decreased significantly, while TAC and GABA levels increased statistically significant. With this study, P CA corrected the deterioration in the oxidant / antioxidant status, suppressed neuro-inflammation, decreased AChE activity, partially normalized neurotransmitters, and decreased the increased WBC count. Necrosis seen in the CIS group in histopathological examinations was never seen in the PCA + CIS group.Conclusions: PCA may provide therapeutic benefit when used in conjunction with CIS.

01 Jan 2024·Integrative Zoology

Antifertility effects of EP‐1 (quinestrol and levonorgestrel) on Pacific rats (Rattus exulans)

Article

Author: Zhang, Zhibin ; Liu, Ming ; Tu, Feiyun ; Wang, Jichao ; Liu, Jing

AbstractPest rodents pose a serious threat to island biodiversity. Fertility control could be an alternative approach to control the impact of rodents on these islands. In this study, we examined the antifertility effects of EP‐1 baits containing quinestrol (E) and levonorgestrel (P) using a dose of 50 ppm E and P at three different ratios (E:P ratio = 1:2, 1:1, and 2:1) on Pacific rats (Rattus exulans) in the Xisha Islands, Hainan, China. Compared to the control group, all animals in EP‐1 treatment groups showed significantly decreased food intake and body weight. In treated males, there were obvious abnormalities in testis structure and a significant decrease of relative seminal vesicle weight, but no significant effect on relative uterine and ovarian weights (g kg−1 body weight), or ovarian structure in females. Adding 8% sucrose to the original 50‐ppm baits (E:P ratio = 1:1) significantly increased bait palatability for males and females. This dose induced uterine edema and abnormalities of ovarian structure in females but had no significant negative effect on the relative testis, epididymis, and seminal vesicle weights (g kg−1 body weight) or sperm density in males. In summary, 50‐ppm EP‐1 (1:1) baits have the potential to disrupt the fertility of females, and 8% sucrose addition to the EP‐1 baits (E:P ratio = 1:1) could improve bait palatability. This dose disrupted the testis structure in males. Future studies are needed to improve bait acceptance and assess the antifertility effects of EP‐1 (1:1) on Pacific rats in captive breeding trials and under field conditions.

31 Dec 2023·Journal of Oral Microbiology

Association of nine pathobionts with periodontitis in four South American and European countries

Article

Author: Mor, Carolina ; Àlvarez, Gerard ; Mendoza, Gerardo ; Huapaya, Enrique ; Isabal, Sergio ; Teughels, Wim ; Arredondo, Alexandre ; Nart, José ; León, Rubén ; Blanc, Vanessa ; Contreras, María José ; Isbej, Lorena ; Laleman, Isabelle

AimOur aim was to compare the prevalence and load of nine pathobionts in subgingival samples of healthy individuals and periodontitis patients from four different countries.MethodsFive hundred and seven subgingival biofilm samples were collected from healthy subjects and periodontitis patients in Belgium, Chile, Peru and Spain. The prevalence and load of Eubacterium brachy, Filifactor alocis, Fretibacterium fastidiosum, Porphyromonas endodontalis, Porphyromonas gingivalis, Selenomonas sputigena, Treponema denticola, Tannerella forsythia and Treponema socranskii were measured by quantitative PCR.ResultsThe association with periodontitis of all species, except for T. socranskii, was confirmed in all countries but Peru, where only P. endodontalis, P. gingivalis and T. denticola were found to be significantly associated. Moreover, most species showed higher loads at greater CAL and PPD, but not where there was BOP. Through Principal Component Analysis, samples showed clearly different distributions by diagnosis, despite observing a smaller separation in Peruvian samples.ConclusionsUnlike prevalence, relative load was found to be a reliable variable to discriminate the association of the species with periodontitis. Based on this, F. alocis, P. endodontalis, P. gingivalis, T. denticola and T. forsythia may be biomarkers of disease in Belgium, Chile and Spain, due to their significantly higher abundance in periodontitis patients.

100 Deals associated with Chloramphenicol/Fradiomycin Sulfate/Prednisolone

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Skin and skin structure infections	Japan	Fuji Chemical Industries Co., Ltd.	15 Mar 1994
Dermatitis	Japan	Alfresa Pharma Corp.	09 Nov 1959
Eczema	Japan	Alfresa Pharma Corp.	09 Nov 1959
Pyoderma	Japan	Alfresa Pharma Corp.	09 Nov 1959
Secondary infection	Japan	Alfresa Pharma Corp.	09 Nov 1959

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2020	Not Applicable	HER2 Positive Breast Cancer Neoadjuvant	215	NACT+p+O	vwmpjxhuvo(pnaohqgudl) = noxzyzqdaa qjgdhsebyw (raubfpsigg ) View more	Positive	25 May 2020
ASCO2018	Not Applicable	HER2 Positive Breast Cancer Neoadjuvant	219	NAC+T	(cvxrskwhcn) = rsojjzzcid qivccdsjrt (avvmxyhrye ) View more	Positive	01 Jun 2018
				NAC+T+P	(cvxrskwhcn) = jewlgujtxn qivccdsjrt (avvmxyhrye ) View more
AACR2017	Phase 2	Metastatic breast cancer	81	Pelareorep + P	(krciddtiqy) = cluubrfrwi zxbklyptbo (llorbyguzu ) View more	Negative	01 Jul 2017
				P	(krciddtiqy) = bokxigoict zxbklyptbo (llorbyguzu ) View more
MOSG (ASCO2006)	Phase 3	Metastatic breast cancer	368	X+P	(xoypwwdnge) = PFS and OS are similar at a median follow-up of 15.5 months famdpyodjp (enkgvvkmtt ) View more	-	20 Jun 2006
				X+T
ASCO2004	Phase 2	Non-Small Cell Lung Cancer Consolidation	-	NVB oral + P	nvusvbywur(kfhbpptpja) = vjiebbflsv inikzmqqkl (jgvedgeoly ) View more	Positive	15 Jul 2004
ASCO2004	Not Applicable	Locally Advanced Head and Neck Squamous Cell Carcinoma Neoadjuvant	718	Regimen A: Ifosfamide	(xhkdbibnyh) = 48.3% patients on D & 49.1% patients on E had grade III & IV neutropenia pbutoemfnd (yajitwwngi ) View more	-	15 Jul 2004
				Regimen B: Ifosfamide with cisplatin (I+P)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Chloramphenicol/Fradiomycin Sulfate/Prednisolone

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation